Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mathilde Guerin

Showing results (11-20 of 15) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 15 results.
Cancer Research|May 20, 2016
Inherent and Tumor-Driven Immune Tolerance in the Prostate Microenvironment Impairs Natural Killer Cell Antitumor ActivityChristine Pasero, Gwenaëlle Gravis, Mathilde Guerin, et al.
Frontiers in Oncology|July 1, 2021
Corrigendum: Gastrointestinal Metastases From Primary Renal Cell Cancer: A Single Center ReviewMaelle Rony, Jean-Philippe Ratone, Jochen Walz, et al.
European Journal of Cancer (Oxford, England : 1990)|September 27, 2017
PIKHER2: A phase IB study evaluating buparlisib in combination with lapatinib in trastuzumab-resistant HER2-positive advanced breast cancerMathilde Guerin, Keyvan Rezai, Nicolas Isambert, et al.
Oncotarget|October 19, 2018
Development of parallel reaction monitoring (PRM)-based quantitative proteomics applied to HER2-Positive breast cancerMathilde Guerin, Anthony Gonçalves, Yves Toiron, et al.
Cancer Treatment Reviews|March 29, 2025
Pharmacology and pharmacokinetics of antibody-drug conjugates, where do we stand?Arthur Géraud, Paul Gougis, Alexandre de Nonneville, et al.
Pageof 2

Showing results (11-20 of 15) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 15 results.
Cancer Research|May 20, 2016
Inherent and Tumor-Driven Immune Tolerance in the Prostate Microenvironment Impairs Natural Killer Cell Antitumor ActivityChristine Pasero, Gwenaëlle Gravis, Mathilde Guerin, et al.
Frontiers in Oncology|July 1, 2021
Corrigendum: Gastrointestinal Metastases From Primary Renal Cell Cancer: A Single Center ReviewMaelle Rony, Jean-Philippe Ratone, Jochen Walz, et al.
European Journal of Cancer (Oxford, England : 1990)|September 27, 2017
PIKHER2: A phase IB study evaluating buparlisib in combination with lapatinib in trastuzumab-resistant HER2-positive advanced breast cancerMathilde Guerin, Keyvan Rezai, Nicolas Isambert, et al.
Oncotarget|October 19, 2018
Development of parallel reaction monitoring (PRM)-based quantitative proteomics applied to HER2-Positive breast cancerMathilde Guerin, Anthony Gonçalves, Yves Toiron, et al.
Cancer Treatment Reviews|March 29, 2025
Pharmacology and pharmacokinetics of antibody-drug conjugates, where do we stand?Arthur Géraud, Paul Gougis, Alexandre de Nonneville, et al.
Pageof 2